Literature DB >> 25985250

Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.

Emilie Viennois1, Yuan Zhao, Didier Merlin.   

Abstract

Diagnostics of inflammatory bowel diseases (IBDs) currently relies on a combination of biological and morphological tests. The current method of diagnostic remains a critical challenge for physicians in part due to their invasiveness and also for their limitations in term of diagnosis, prognosis, disease activity and severity assessment, and therapeutic outcomes. Laboratory biomarkers can be used in the diagnosis and management of IBD, but none of them has been proven to be ideal. Increasing efforts are being made to discover new biomarkers that can discriminate between the types of IBD, predict future responses to treatment, and aid in differential diagnosis, treatment planning, and prognosis prediction. This review addresses the potential for current biomarkers and the emergence of the concept of biomarker signatures in IBD diagnostic and personalized medicine.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25985250      PMCID： PMC4567401          DOI： 10.1097/MIB.0000000000000444

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


  99 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

2.  C-reactive protein in acute coronary disease; a clinical study.

Authors:  K HALLSTROM; O WAGER
Journal:  Cardiologia       Date:  1956

3.  Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.

Authors:  Keun Hur; Yuji Toiyama; Aaron J Schetter; Yoshinaga Okugawa; Curtis C Harris; C Richard Boland; Ajay Goel
Journal:  J Natl Cancer Inst       Date:  2015-02-06       Impact factor: 13.506

4.  Identification of circulating microRNA signatures for breast cancer detection.

Authors:  Maurice Chan; Chiew Suan Liaw; Shen Mo Ji; Hwee Huang Tan; Chow Yin Wong; Aye Aye Thike; Puay Hoon Tan; Gay Hui Ho; Ann Siew-Gek Lee
Journal:  Clin Cancer Res       Date:  2013-06-24       Impact factor: 12.531

5.  Identification of microRNAs associated with ileal and colonic Crohn's disease.

Authors:  Feng Wu; Simin Zhang; Themistocles Dassopoulos; Mary L Harris; Theodore M Bayless; Stephen J Meltzer; Steven R Brant; John H Kwon
Journal:  Inflamm Bowel Dis       Date:  2010-10       Impact factor: 5.325

6.  Circulating microRNA is a biomarker of pediatric Crohn disease.

Authors:  Adam M Zahm; Meena Thayu; Nicholas J Hand; Amber Horner; Mary B Leonard; Joshua R Friedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-07       Impact factor: 2.839

7.  Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.

Authors:  Josie Hayes; Helene Thygesen; Charlotte Tumilson; Alastair Droop; Marjorie Boissinot; Thomas A Hughes; David Westhead; Jane E Alder; Lisa Shaw; Susan C Short; Sean E Lawler
Journal:  Mol Oncol       Date:  2014-11-28       Impact factor: 6.603

8.  Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).

Authors:  Andrew B Nixon; Herbert Pang; Mark D Starr; Paula N Friedman; Monica M Bertagnolli; Hedy L Kindler; Richard M Goldberg; Alan P Venook; Herbert I Hurwitz
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

9.  Identification of unique microRNA signature associated with lupus nephritis.

Authors:  Jeannie L Te; Igor M Dozmorov; Joel M Guthridge; Kim L Nguyen; Joshua W Cavett; Jennifer A Kelly; Gail R Bruner; John B Harley; Joshua O Ojwang
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

10.  Fecal lactoferrin: a new parameter to monitor infliximab therapy.

Authors:  Stephan Buderus; James Boone; David Lyerly; Michael J Lentze
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199
View more
  13 in total

1.  Do ginger-derived nanoparticles represent an attractive treatment strategy for inflammatory bowel diseases?

Authors:  Mingzhen Zhang; James F Collins; Didier Merlin
Journal:  Nanomedicine (Lond)       Date:  2016-11-04       Impact factor: 5.307

2.  Crohn's disease-related single nucleotide polymorphisms are associated with ileal pouch afferent limb stenosis.

Authors:  Stephen J O'Brien; Jacob Hallion; Katharina M Scheurlen; Casey Fiechter; James Burton; Mason Paas; Miranda Schmidt; Sarah Gardner; Maurice R Eichenberger; Jianmin Pan; Shesh Rai; Susan Galandiuk
Journal:  J Gastrointest Surg       Date:  2021-01-14       Impact factor: 3.452

3.  Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis.

Authors:  Lu Liu; Dan Pu; Dandan Wang; Muhan Zhang; Chuan Zhou; Zhe Zhang; Baisui Feng
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

4.  Candida utilis yeast as a functional protein source for Atlantic salmon (Salmo salar L.): Local intestinal tissue and plasma proteome responses.

Authors:  Felipe Eduardo Reveco-Urzua; Mette Hofossæter; Mallikarjuna Rao Kovi; Liv Torunn Mydland; Ragnhild Ånestad; Randi Sørby; Charles McLean Press; Leidy Lagos; Margareth Øverland
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

5.  Inducible nitric oxide synthase as a potential blood-based biomarker in inflammatory bowel diseases.

Authors:  Saeed Baranipour; Azade Amini Kadijani; Durdi Qujeq; Shabnam Shahrokh; Mehrdad Haghazali; Alireza Mirzaei; Hamid Asadzadeh-Aghdaei
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018

6.  Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.

Authors:  Rahul Kalla; Nicholas A Kennedy; Nicholas T Ventham; Ray K Boyapati; Alex T Adams; Elaine R Nimmo; Micaela R Visconti; Hazel Drummond; Gwo-Tzer Ho; Rebecca J Pattenden; David C Wilson; Jack Satsangi
Journal:  Am J Gastroenterol       Date:  2016-09-06       Impact factor: 12.045

7.  Serum miRNA signature diagnoses and discriminates murine colitis subtypes and predicts ulcerative colitis in humans.

Authors:  Emilie Viennois; Yuan Zhao; Moon Kwon Han; Bo Xiao; Mingzhen Zhang; Meena Prasad; Lixin Wang; Didier Merlin
Journal:  Sci Rep       Date:  2017-05-31       Impact factor: 4.379

Review 8.  Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.

Authors:  Bjoern Titz; Raffaella M Gadaleta; Giuseppe Lo Sasso; Ashraf Elamin; Kim Ekroos; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng
Journal:  Int J Mol Sci       Date:  2018-09-15       Impact factor: 5.923

Review 9.  Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs.

Authors:  Romy M Heilmann; Jörg M Steiner
Journal:  J Vet Intern Med       Date:  2018-09-17       Impact factor: 3.333

10.  Biomarker discovery in inflammatory bowel diseases using network-based feature selection.

Authors:  Mostafa Abbas; John Matta; Thanh Le; Halima Bensmail; Tayo Obafemi-Ajayi; Vasant Honavar; Yasser El-Manzalawy
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.